This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Schnoll RA , Martinez E , Tatum KL , Weber DM , Kuzla N , Glass M , Ridge JA , Langer C , Miyamoto C , Wileyto EP , Leone F
A bupropion smoking cessation clinical trial for cancer patients
Cancer Causes & Control. 2010 Jun;21(6) :811-820
AbstractMany cancer patients continue to smoke post diagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation. This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7-day point-prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects. There was no main effect of bupropion vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38-4.81, p = .64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02-0.80, p = .03). Bupropion increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, bupropion reduced withdrawal symptoms and improved quality of life vs. placebo. For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with bupropion or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.
NotesSchnoll, Robert A. Martinez, Elisa Tatum, Kristina L. Weber, Dorothy M. Kuzla, Natalie Glass, Marcella Ridge, John A. Langer, Corey Miyamoto, Curtis Wileyto, E. Paul Leone, Frank National Cancer Institute [R01 CA95678] The authors would like to thank Ms. Jeanne Pomenti for assisting with the preparation of this manuscript. This study was funded by grant R01 CA95678 from the National Cancer Institute. Transdermal nicotine patches were provided free-of-charge by GlaxoSmithKline. All sites provided Institutional Review Board approval. All patients provided informed consent for this study. 52 Springer; van godewijckstraat 30, 3311 gz dordrecht, netherlands 596ua